The Food and Drug Administration (FDA) announces that it has approved Fluad, the first seasonal influenza vaccine containing an adjuvant. Fluad, which is manufactured using an egg-based process, is formulated with the adjuvant MF59, an oil-in-water emulsion of squalene oil. The study showed that Fluad induced antibody levels that were comparable to the levels induced by Agriflu [i.e., no better.] Fluad was approved using the accelerated approval regulatory pathway, which allows the FDA to approve products for serious or life-threatening diseases based on evidence that the product has an effect on an outcome that is reasonably likely to predict clinical...